Key Highlights
- Phase 1/2 clinical update on IMA402 scheduled for October 24 at ESMO.
- Phase 1a data showed a 30% confirmed objective response rate at the recommended dose.
- Responses included 29% in melanoma and two of three patients in ovarian cancer.
- Immatics shares trade near $9.59, with a market value of about $1.29 billion.
Immatics N.V. (NASDAQ: IMTX) is scheduled to provide a Phase 1/2 clinical data update on IMA402 in solid tumors at the ESMO 2026 congress on October 24.
What Happened
Phase 1a results, noted November 12, 2025, showed deep and durable responses with favorable tolerability in heavily pre-treated solid tumor patients.
IMA402 achieved a 30% confirmed objective response rate at the recommended Phase 2 dose, including a 29% response rate in melanoma and responses in two of three ovarian cancer patients.
Market Reaction
Immatics, valued at approximately $1.29 billion, traded near $9.59 per share, up $0.19, or 2.02%, according to the disclosed pipeline database.
Outlook
An updated Phase 1/2 clinical data set is scheduled to be shared at ESMO on October 24, 2026.
What is IMA402?
IMA402 is a Phase 1/2 clinical-stage candidate from Immatics being studied across solid tumors, including melanoma and ovarian cancer.
What has prior IMA402 data shown?
Phase 1a data noted November 12, 2025 showed a 30% confirmed objective response rate at the recommended Phase 2 dose.
When is the next IMA402 data update?
Immatics is scheduled to share an updated Phase 1/2 data set at ESMO on October 24, 2026.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...